Oxalato Platinum Research Articles

Probing the Interaction of Newly Synthesized Pt(II) Complex on Human Serum Albumin Using Competitive Binding Site Markers.

Considering the importance of pharmacology and the influence of drugs on biological materials, the effects of a newly designed and synthesized platin complex (2,2'-Bipyridine-3,3'-dicarboxylic acid, oxalato Platinum(II), as an antitumor drug was tested on the structure of blood carrier protein of human serum albumin (HSA) using various spectroscopic techniques including UV-visible, fluorescence, and circular dichroism at 25 and 37°C. Results of the fluorescence measurements revealed that adding the complex caused reduction in intrinsic fluorescence emission of HSA resulted from dynamic quenching of HSA. The number of binding sites and binding constants were calculated at both temperatures of 25 and 37°C. In addition, in order to identify the complex's binding site on HSA employing spectroscopy, the competitive studies were followed using warfarin, digitoxin and ibuprofen as site markers of Sudlow sites I, II and III. Competitive binding test results have shown that Pt(II) complex bind on the warfarin binding site (or Sudlow sites I) on HSA. Besides, a reduction in thermal stability for HSA was observed in the presence of the newly designed Pt(II) complex.

Acute Myeloid Leukemia Secondary to Oxaliplatin Treatment for Esophageal Cancer

Introduction Therapy-related leukemias (TRL) are neoplasms that occur as a late consequence after exposure to certain cytotoxic agents or radiation. Several cytotoxic agents have been implicated in the development of TRL. These include alkylating agents (melphalan, cyclophosphamide); platinum compounds (cisplatin, carboplatin); and topoisomerase-2 inhibitors, such as etoposide, daunorubicin, and mitoxantrone. The latency period between exposure and the development of TRL varies from a few months to several years, depending on the cytotoxic agent. TRL after exposure to alkylating agents is thought to typically develop after a latency of more than 3 years; whereas, that which develops with use of opoisomerase-2 inhibitors typically present within 1 to 3 years. Cisplain, as well as carboplatin, used in the treatment of a wide variety of alignancies, have previously been linked with TRL, whereas, the role f oxaliplatin (1,2-diaminocyclohexane oxalato platinum) (OXP), a

Chiral palladium(II) and platinum(II) complexes of diaminocyclohexane: X-ray structures of (1 R,2 R)-(−)-1,2-diaminocyclohexane dihydrochloride and its corresponding oxalato platinum(II) complex

The nucleophilic substitution reaction of the enantiomerically pure ligand, (1 R,2 R)-(−)-1,2-diaminocyclohexane [DACH] ( 1) with cis-bis(benzonitrile)palladium(II) dichloride [(PhCN) 2PdCl 2] leads to the formation of the complex [(DACH)PdCl 2] ( 2) in a high yield. The reaction of the corresponding platinum(II) complex [(PhCN) 2PtCl 2] with DACH, under the same reaction conditions, surprisingly, took a different course, in which nucleophilic addition to the benzonitrile ligand occurred forming an enantiomerically pure amidine complex [(PhCNHNH(C 6H 10)NH 2)Pt(NCPh)Cl]Cl ( 3), where the nitrogen ligand form a seven-membered chelate around the central atom. The aqua and oxalato derivatives of complex 2, [(DACH)Pd(H 2O) 2](NO 3) 2 ( 4) and [(DACH)Pd(C 2O 4)] ( 5) have also been prepared and characterized. The platinum analogue complex to 5, [(DACH)Pt(C 2O 4)] ( 6), was prepared starting from the enantiomerically pure isomer ( 1) and the platinum salt K 2PtX 4 (X=Cl, I). According to X-ray structural analysis carried out on the complex, the product does not consist of just the desired isomer, but a mixture of both the trans- l ( trans-(−)-1 R,2 R) and trans- d ( trans-(+)-1 S,2 S) isomers. No retention of optical isomerism was observed. The single crystal structural analysis was also carried out on the ligand N, N′-(1 R,2 R)-(−)-diaminocyclohexane dihydrochloride (DACH·2HCl)] ( 1a). The result indicates, however, that only the R, R-isomer exists in the free ligand.